重要公告： 福田汽车：拟不超25亿元参与认购北汽蓝谷定增股份 中国石化：一季度净利润132.64亿元同比下降27.6% 沪市重要公告： 药明康德：一季度净利润36.72亿元同比增长89.06% 中金公司：一季度净利润20.42亿元同比增长64.85% 赛特新材：董事长自愿放弃领薪高管人员自愿降薪 上海医药：一季度净利润13.33亿元同比下降13.56% 上海医药（601607）4月28日晚间发布一季报，2025年一季度实现营业收入707.63亿元，同比增长 0.87%；净利润13.33亿元，同比下降13.56%。其中，工业板块贡献利润5.32亿元；商业板块贡献利润 8.34亿元；主要参股企业贡献利润1.96亿元。 传音控股：一季度净利润4.9亿元同比下降69.87% 传音控股（688036）4月28日晚间发布一季报，2025年第一季度营收为130.04亿元，同比下降25.45% （调整后）；净利润为4.9亿元，同比下降69.87%（调整后）。净利润下降主要是受市场竞争以及供应 链成本综合影响，营业收入及毛利额减少所致。 浙能电力：一季度净利润10.74亿元同比下降40.81% 浙能电力（600023）4月28 ...

Group 1 - The company achieved operating revenue of 10.841 billion yuan in the first quarter, representing a year-on-year growth of 0.62% [1] - The net profit attributable to shareholders of the listed company was 1.935 billion yuan, showing a year-on-year increase of 13.67% [1]

Financial Performance - The company's revenue for Q1 2025 was CNY 10,841,237,721.29, representing a year-on-year increase of 0.62% compared to CNY 10,774,290,921.49 in the same period last year[9]. - Net profit attributable to shareholders for Q1 2025 was CNY 1,934,639,584.60, an increase of 13.67% from CNY 1,701,931,446.00 in the previous year[9]. - The net profit after deducting non-recurring gains and losses was CNY 1,887,406,845.46, up 11.65% from CNY 1,690,411,601.12 year-on-year[9]. - The industrial revenue for Q1 2025 was CNY 4.47 billion, with a year-on-year growth of CNY 317 million, resulting in a growth rate of 7.63%[9]. - The gross profit margin for the industrial segment was 68.34%, an increase of 1.76 percentage points compared to the same period last year[9]. - Total operating revenue for the current period reached ¥10,841,237,721.29, an increase from ¥10,774,290,921.49 in the previous period, reflecting a growth of approximately 0.62%[28]. - Operating profit for the current period is CNY 2,255,305,450.43, up from CNY 1,918,019,878.04, reflecting a growth of approximately 17.6%[29]. - The total comprehensive income attributable to the parent company is CNY 1,934,668,054.49, compared to CNY 1,700,922,114.44 in the previous period, indicating an increase of about 13.7%[30]. Cash Flow and Assets - The net cash flow from operating activities increased by 35.39% to CNY 713,597,559.65, compared to CNY 527,059,804.98 in the same period last year[9]. - The company's cash and cash equivalents increased to ¥11,061,687,096.94 from ¥10,887,983,161.30, showing a growth of approximately 1.59%[25]. - The company's retained earnings increased to ¥18,915,978,970.36 from ¥16,981,339,385.76, reflecting a growth of about 11.41%[28]. - The company's total assets at the end of Q1 2025 were CNY 54,253,026,317.64, reflecting a 2.53% increase from CNY 52,914,181,333.05 at the end of the previous year[9]. - Total liabilities decreased to ¥13,458,057,151.71 from ¥14,048,096,770.78, a reduction of approximately 4.20%[27]. - The company's cash flow from operating activities shows a net inflow of CNY 713,597,559.65, compared to CNY 527,059,804.98 in the previous period, marking an increase of about 35.3%[31]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 170,416[16]. - Yunnan State-owned Equity Operation Management Co., Ltd. holds 26.20% of shares, totaling 467,431,774 shares, with 115,500,000 shares pledged[16]. - Xinhua Duhua Industrial Group Co., Ltd. holds 24.42% of shares, totaling 435,742,244 shares, with 336,894,000 shares pledged[16]. - The top 10 shareholders hold significant stakes, with the largest shareholder holding over 26%[16]. - The company is actively managing shareholder equity, including pledges and releases, to optimize capital structure[21][22]. Operational Metrics - The weighted average return on equity increased by 0.68 percentage points to 4.86% from 4.18% year-on-year[9]. - The company reported a significant increase in accounts receivable by 10.08% to CNY 10,923,656,861.70, primarily due to an increase in the commercial segment's receivables[13]. - Inventory decreased to ¥5,970,435,025.83 from ¥6,294,368,316.30, reflecting a decline of approximately 5.15%[25]. - Research and development expenses for the current period were ¥60,122,221.90, compared to ¥57,282,132.50 in the previous period, showing an increase of about 3.22%[28]. Corporate Actions - The company announced the retirement of its Chief Innovation Officer and Chief Compliance Officer due to reaching the legal retirement age[20]. - The company completed the establishment of the Yunnan Traditional Chinese Medicine Health Innovation Equity Investment Fund, with registration and private fund filing completed[19]. - Yunnan State-owned Equity Operation Management Co., Ltd. released 52,171,840 shares (2.92% of total shares) from pledge on January 10, 2025[21]. - Yunnan State-owned Equity Operation Management Co., Ltd. pledged 48,000,000 shares (2.69% of total shares) on January 18, 2025[22]. - Yunnan State-owned Equity Operation Management Co., Ltd. completed a share buyback of 17,807,463 shares, representing 0.9980% of total shares, with a total investment of RMB 950,379,399.02[23].

Core Points - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7479.61 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 0.64% in the past month, increased by 3.66% over the last three months, and has risen by 0.48% year-to-date [1] Industry Composition - The CSI 300 Pharmaceutical and Biotechnology Index is composed of 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] - The index is based on the performance of all securities in the CSI 300 Index classified by industry, with a base date of December 31, 2004, and a base point of 1000.0 [1] Index Holdings - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: - Heng Rui Medicine (24.75%) - WuXi AppTec (15.82%) - Pian Zai Huang (6.85%) - Yunnan Baiyao (5.7%) - Kelun Pharmaceutical (4.68%) - New Horizon (3.79%) - East China Pharmaceutical (3.64%) - Shanghai Raist (3.44%) - Fosun Pharma (3.38%) - Changchun High-tech (3.17%) [1] Market Distribution - The market distribution of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.33% and the Shenzhen Stock Exchange accounts for 36.67% [2] Sector Breakdown - The sector breakdown of the index holdings indicates that: - Chemical drugs account for 42.69% - Pharmaceutical and biotechnology services account for 21.06% - Traditional Chinese medicine accounts for 19.74% - Biological drugs account for 16.51% [2] Sample Adjustment - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with sample changes, and any special events affecting a sample company's industry classification will lead to corresponding adjustments in the index [2]

Group 1: Investment and Growth Strategy - The company plans to optimize its industrial portfolio through both "internal" and "external" collaborative development, focusing on strategic mergers and partnerships to overcome growth bottlenecks and achieve sustainable development [2][3]. Group 2: Pharmaceutical Business Performance - In 2024, the pharmaceutical segment achieved significant growth by positioning itself as the "leading brand in comprehensive pain management," enhancing product visibility and ecosystem through clinical research and marketing strategies [4][5]. - The pharmaceutical group reported steady progress in clinical studies for various products, including those targeting diabetic foot and bone pain, contributing to broader application scenarios [4]. Group 3: Traditional Chinese Medicine (TCM) Supply Chain Development - The company is committed to developing a world-class modern TCM industry, with initiatives in seed cultivation, planting, processing, and branding, including the establishment of a specialized seed company [6][7]. - In 2024, the company reported a 180% increase in the production of fresh medicinal materials and a 182% increase in food and health product output, supporting high-quality development [6]. Group 4: Health Products Performance - The health product segment, particularly the Yangyuanqing hair care line, achieved sales revenue of 422 million yuan in 2024, marking a 30.3% year-on-year growth [8]. Group 5: Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with promising results indicating excellent stability and safety [9][11]. Group 6: Health Product Channel Development - The company maintains a comprehensive national sales team for health products, with a leading market share in oral care products, and is optimizing both traditional and emerging sales channels [12]. Group 7: Digital Transformation Initiatives - The company is implementing a digital development plan (2022-2026) that leverages AI and data to enhance all aspects of the supply chain, aiming for a smart and green transformation in the TCM industry [13][14]. Group 8: Provincial Pharmaceutical Company Performance - The provincial pharmaceutical company achieved a main business revenue of 24.607 billion yuan in 2024, with a 0.48% year-on-year growth, and significant increases in non-pharmaceutical business sales [15][16].

云南白药集团股份有限公司 投资者调研会议记录表 1 / 2 | | 药品事业群总经理-郑祥伟 | | --- | --- | | | 健康品事业群总经理-黄玉敏 | | | 中药资源事业群总经理-李春平 | | | 省医药有限公司总经理-朱家龙 | | | 证券事务代表-李孟珏 | | | 投资者关系管理-杨可欣 | | 投资者关系活动主要 | 了解公司生产经营情况等相关问题 | | 内容介绍 | | | 附件清单 | 会议记录 | 2 / 2 编号：20-2504-15 | | ☑特定对象调研 | □分析师会议 | | --- | --- | --- | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | ☑现场参观 | □一对一沟通 | | | □其他（电话会议） | | | 参与单位名称及人员 | 中信证券-陈竹、刘晓岚、宋硕、李文涛 | | | | 中信建投-刘若飞、沈兴熙 | | | | 国泰海通-张澄、唐玉青 | | | | 华泰证券-张云逸 | | | | 富国基金-黄致君 | | | 姓名 | 大成基金-王敏杰 | | | | 泰康资 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 云南白药集团股份有限公司（以下简称"公司"或"本公司"）2024年度权益分派方案已获2025年4月21日 召开的公司2024年度股东大会审议通过，股东大会决议公告刊登于2025年4月22日的《中国证券报》 《上海证券报》《证券时报》及巨潮资讯网（http://www.cninfo.com.cn）。 一、股东大会审议通过权益分派方案情况 1、本公司获股东大会审议通过的2024年度权益分派具体方案为：以公司现有总股本1,784,262,603股为 基数，向全体股东每10股派发现金红利11.85元（含税），送红股0股，不以资本公积金转增股本，本次 现金分红总金额2,114,351,184.56元。按照本方案分配比例，以分配方案未来实施时股权登记日享有利润 分配权利的股份数量为基数，从而最终确定分配总额。其余未分配利润留待以后年度分配。在公司利润 分配预案披露之日起至实施权益分派股权登记日期间，公司享有利润分配权的股份总额由于增发新股、 股权激励行权、可转债转股、股份回 ...

1 Topic Steady Progress with Legacy of Baiyao Innovation-driven Exploration of New Horizons in TCM Green Development for Deepening Ecological Civilization People First for Strengthening the Foundation of Talent Cultivating Virtue and Embracing Responsibilities Appendix Feedback Form | Leadership in Party Building | 27 | | --- | --- | | Operation of the Board of Directors | 29 | | Risk Management | 31 | | Business Ethics | 33 | | Product Quality | 37 | | --- | --- | | R&D Innovation | 41 | | Customer Service ...

股票代码：000538 股票简称：云南白药 公告编号：2025-16 2、公司已于 2024 年 11 月完成 2024 年特别分红利润分派，每 10 股派送 现金 12.13 元（含税），现金分红金额共计 2,164,310,537.44 元（含税）。本 次拟实施的现金分红总金额 2,114,351,184.56 元，与 2024 年已实施的特别分 红合并计算，以 2024 年末公司总股本 1,784,262,603 股为基数，2024 年度每 10股累计派送现金23.98 元（含税），累计现金红利总额合计为4,278,661,722.00 元（含税），占 2024 年度公司归属于上市公司股东净利润的 90.09%。 1 / 3 3、本次实施的权益分派方案与股东大会审议通过的权益分派方案一致。 4、本次实施权益分派方案距离股东大会审议通过的时间没有超过两个月。 云南白药集团股份有限公司 2024 年度权益分派实施公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"或"本公司"）2024 年度权 益分派方案已获 2 ...

股票代码：000538 股票简称：云南白药 公告编号：2025-15 云南白药集团股份有限公司 2024年度股东大会决议公告 重要提示：本公司及董事会全体成员保证信息披露内容的真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重要提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 1、股东出席的总体情况： （1）现场会议召开时间：2025 年 4 月 21 日上午 9:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的 时间为 2025 年 4 月 21 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的时间为 2025 年 4 月 21 日 9:15-15:00。 2、现场会议召开地点：云南省昆明市呈贡区云南白药街 3686 号云 南白药集团股份有限公司总部白药空间二楼会议室。 3、会议召开方式：本次股东大会以现场表决和网络投票相结合的方 式召开。公司将通过深圳证券交易所交易系统和互联网投票系统 1 / 7 （http ...